AUTHORS
Sanghee Hong, MD, Yan Li2, Gwynn Long, MD3, Cristina Gasparetto, MD4, Taewoong Choi, MD5, Edwin Alyea, MD6, Stefanie Sarantopoulos, MD, PhD7, Mitchell Horwitz I, MD8, Nelson Chao, MD9, Thomas W LeBlanc, MD, MA, MHS10, Anthony Sung, MD11
AFFILIATIONS
1 Duke Blood Cancer Center, Durham, North Carolina, United States
2 Duke Cancer Institute, Durham, United States
3 Duke Blood Cancer Center, Durham, North Carolina, United States
4 Duke Blood Cancer Center, Durham, North Carolina, United States
5 Duke Blood Cancer Center, Durham, North Carolina, United States
6 Duke Blood Cancer Center, Durham, North Carolina, United States
7 Duke Blood Cancer Center, Durham, North Carolina, United States
8 Duke Blood Cancer Center, Durham, North Carolina, United States
9 Duke Blood Cancer Center, Durham, North Carolina, United States
10 Duke Blood Cancer Center, Durham, United States
11 University of Kansas Medical Center, Kansas City, Kansas, United States
ABSTRACT
Background: Return to work (RTW) represents a critical measure of functional and social recovery after cancer treatment. Although survival after allogeneic hematopoietic cell transplantation (HCT) has improved substantially, only 50-60% of survivors resume employment, underscoring a persistent gap in survivorship care. We sought to identify pre- and post-transplant factors associated with successful RTW and define potentially modifiable targets for survivorship interventions.
Methods: We analyzed prospectively collected data from Duke Health's Comprehensive Pre- and Post-Optimization Program (C-POP), including 216 adult allogeneic HCT recipients between 2018 and 2025 who survived at least 6 months post-HCT and completed serial work assessments before and after HCT. Death before RTW was treated as a competing risk, with 36 total deaths by 2 years post-HCT. Patients who were retired (n=57), permanently disabled (n=19), unemployed before HCT (n=13), students (n=1), or homemakers (n=1) were excluded from RTW analyses. The primary outcome was RTW by 2 years after HCT. Clinical characteristics, socioeconomic factors, and longitudinal patient-reported assessments of cognition, depression, nutrition, and quality of life collected before and after HCT were evaluated as potential predictors of RTW using univariable and multivariable analyses.
Results: Among 125 allogeneic HCT survivors who were employed before HCT, RTW rates were 57% (47/82) at 6 months, 61% (42/69) at 1 year, and after HCT. Notably, pre-HCT quality-of-life was associated with subsequent RTW success. Patients who returned to work had higher pre-HCT FACT-BMT scores (median 120.2 vs. 110.4, p=0.046) and Functional Assessment of Cancer Therapy (FACT)-General (G) scores (median 89 vs. 82.5, p=0.019). These differences persisted after transplantation, with higher FACT-Blood and Marrow Transplant (BMT), FACT-G, and FACT-Trial Outcome Index (TOI) scores among patients who returned to work at 6 months and 1 year after HCT (all p<0.05).
Pre-HCT socioeconomic factors were strongly associated with RTW after HCT. RTW rates increased with educational attainment, from 50% among patients with high school education to 83% among those with master's or doctoral degrees (p=0.024). Patients with Medicare (75%) or private insurance (73%) had higher RTW rates compared with those with other government insurance (50%) or Medicaid (14%, p=0.0075). In multivariable analysis, non-private insurance (Odds Ratio [OR] 0.226, 95% Confidence Interval [CI] 0.057-0.903) and reduced-intensity conditioning (OR 0.137, 95% CI 0.028-0.666) were associated with lower odds of RTW. Other baseline clinical characteristics, including diagnosis, donor type, disease risk, and comorbidity index, were not associated with RTW.
Among survivors evaluable for RTW assessment, chronic graft-versus-host disease (GVHD) was associated with lower RTW between 1-2 years post-HCT (59% vs. 77%, p=0.033), but not between 6 months-1 year post-HCT. Patients who returned to work were less likely to have chronic GVHD by 2 years (59% vs. 88%, p=0.031), with a trend toward lower rates of grade II-IV chronic GVHD (50% vs. 59%, p=0.057). No other transplant outcomes were significantly associated with RTW, potentially reflecting statistical power.
Early post-transplant recovery domains identified patients at risk for delayed RTW. At 6 months post-HCT, patients who returned to work demonstrated better cognitive performance by Montreal Cognitive Assessment (MoCA) score (median 29 vs. 28, p=0.008) and a trend toward lower depression severity by Patient Health Questionnaire-9 (PHQ-9) score (p=0.051). At 1 year post-HCT, patients returning to work were less likely to have nutritional risk on Perioperative Nutrition Screen (PONS; p=0.011).
Conclusion: In this cohort of allogeneic HCT survivors who were employed pre-HCT, successful RTW after allogeneic HCT was associated with a combination of baseline patient characteristics and post-transplant recovery measures. Baseline socioeconomic factors and chronic GVHD identified survivors at highest risk for delayed or unsuccessful RTW, whereas baseline QOL and post-HCT QOL, cognitive, and nutritional status were associated with successful early work reintegration. These findings support incorporation of RTW risk assessment into survivorship care to enable early, targeted interventions addressing functional impairment, cognitive decline, nutritional risk, and socioeconomic barriers.
DISCLOSURES
Sanghee Hong, MD: Sanofi - Honoraria; Incyte - Honoraria; Cullinan Therapeutics - Research Funding; Gamide Cell - Research Funding; Incyte - Consultancy (Includes expert testimony); Geron - Consultancy (Includes expert testimony)